The complex world of proteins: Structure, function, and oligomerization of frataxin. Christopher Söderberg; University dissertation from Department of Chemistry, Lund University (2013-09-27)
Keywords: Friedreich's ataxia, Frataxin, self-assembly, protein-protein interaction, iron homeostasis, SAXS, cross-linking.
Full text is not available.
Monday, September 9, 2013
The legal imperative for treating rare disorders
The legal imperative for treating rare disorders. Hanna I Hyry, Jonathan CP Roos, Jeremy Manuel and Timothy M Cox; Orphanet Journal of Rare Diseases 2013, 8:135 doi:10.1186/1750-1172-8-135
FULL TEXT PDF
FULL TEXT PDF
Sunday, September 8, 2013
Mitochondrial iron transport and homeostasis in plants
Mitochondrial iron transport and homeostasis in plants. Anshika Jain and Erin L. Connolly. Front. Plant Sci., 06 September 2013 | doi: 10.3389/fpls.2013.00348
"Frataxin functions in plants"
FULL TEXT PDF
"Frataxin functions in plants"
FULL TEXT PDF
Friday, September 6, 2013
How to Design a Cell or Gene Therapy Clinical Trial: Advice from the FDA
How to Design a Cell or Gene Therapy Clinical Trial: Advice from the FDA. Adrian P. Gee; Molecular Therapy (2013); 21 9, 1639–1640. doi:10.1038/mt.2013.172
FULL TEXT PDF
FULL TEXT PDF
Friedreich's ataxia research leads to a new understanding of the disease
Friedreich's ataxia research leads to a new understanding of the disease .
06/09/2013. Researchers at the University of Minnesota are using magnetic resonance spectroscopy to better understand how Friedreich's ataxia affects both the brain and spinal cord.
06/09/2013. Researchers at the University of Minnesota are using magnetic resonance spectroscopy to better understand how Friedreich's ataxia affects both the brain and spinal cord.
Ataxie de Friedreich : essai ACTFRIE
Ataxie de Friedreich : essai ACTFRIE.
L'objectif de l'essai ACTFRIE, soutenu financièrement par l'AFM-Téléthon, est d'évaluer l'efficacité de la pioglitazone comparativement à un placebo sur l'atteinte neurologique des personnes atteintes de maladie de Friedreich.
Les 40 participants prévus pour cet essai sont inclus. L'essai, qui a démarré en décembre 2008, est toujours en cours. Sa fin est prévue en avril 2014 et les premiers résultats pourraient être disponibles fin 2014.
L'objectif de l'essai ACTFRIE, soutenu financièrement par l'AFM-Téléthon, est d'évaluer l'efficacité de la pioglitazone comparativement à un placebo sur l'atteinte neurologique des personnes atteintes de maladie de Friedreich.
Les 40 participants prévus pour cet essai sont inclus. L'essai, qui a démarré en décembre 2008, est toujours en cours. Sa fin est prévue en avril 2014 et les premiers résultats pourraient être disponibles fin 2014.
Thursday, September 5, 2013
A mitochondrial implication in a Tunisian patient with Friedreich's ataxia-like
A mitochondrial implication in a Tunisian patient with Friedreich's ataxia-like. Une implication mitochondriale chez un patient tunisien atteint d’une ataxie de Friedreich-like. M. Maalej, E. Mkaouar-Rebai, M. Mnif, N. Mezghani, I. Ben Ayed, I. Chamkha, M. Abid, F. Fakhfakh; Pathologie Biologie, Available online 4 September 2013
Friedreich Ataxia Patient Tissues Exhibit Increased 5-Hydroxymethylcytosine Modification and Decreased CTCF Binding at the FXN Locus
Friedreich Ataxia Patient Tissues Exhibit Increased 5-Hydroxymethylcytosine Modification and Decreased CTCF Binding at the FXN Locus . Sahar Al-Mahdawi, Chiranjeevi Sandi, Ricardo Mouro Pinto, Mark A. Pook; PLoS ONE 8(9): e74956. doi:10.1371/journal.pone.0074956
FULL TEXT PDF
FULL TEXT PDF
Wednesday, September 4, 2013
A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins
A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins. Pierre Chapdelaine, Zoé Coulombe, Amina Chikh, Catherine Gérard and Jacques P Tremblay. Molecular Therapy Nucleic Acids (2013) 2, e119; doi:10.1038/mtna.2013.41
Published online 3 September 2013.
OPEN
FULL TEXT PDF
Published online 3 September 2013.
OPEN
FULL TEXT PDF
Saturday, August 31, 2013
Energy failure—does it contribute to neurodegeneration?
Energy failure—does it contribute to neurodegeneration?. Divya Pathak, Amandine Berthet and Ken Nakamura; Annals of Neurology, Accepted manuscript online: 22 AUG 2013 04:13PM EST | DOI: 10.1002/ana.24014
Energy failure has never been directly demonstrated in affected neurons in these diseases, nor has it been proved to produce degeneration in disease models but energy failure from mitochondrial dysfunction is proposed to be a central mechanism leading to neuronal death in a range of neurodegenerative diseases.
Energy failure has never been directly demonstrated in affected neurons in these diseases, nor has it been proved to produce degeneration in disease models but energy failure from mitochondrial dysfunction is proposed to be a central mechanism leading to neuronal death in a range of neurodegenerative diseases.
Subscribe to:
Posts (Atom)
